Synergizing Attribute-Guided Latent Space Exploration (AGLSE) with Classical Molecular Simulations to Design Potent Pep-Magnet Peptide Inhibitors to Abrogate SARS-CoV-2 Host Cell Entry.

Publication date: Jun 07, 2025

The COVID-19 infection, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has evoked a worldwide pandemic. Even though vaccines have been developed on an enormous scale, but due to regular mutations in the viral gene and the emergence of new strains could pose a more significant problem for the population. Therefore, new treatments are always necessary to combat future pandemics. Utilizing an antiviral peptide as a model biomolecule, we trained a generative deep learning algorithm on a database of known antiviral peptides to design novel peptide sequences with antiviral activity. Using artificial intelligence (AI), specifically variational autoencoders (VAE) and Wasserstein autoencoders (WAE), we were able to generate a latent space plot that can be surveyed for peptides with known properties and interpolated across a predictive vector between two defined points to identify novel peptides that exhibit dose-responsive antiviral activity. Two hundred peptide sequences were generated from the trained latent space and the top peptides were subjected to a molecular docking study. The docking analysis revealed that the top four peptides (MSK-1, MSK-2, MSK-3, and MSK-4) exhibited the strongest binding affinity, with docking scores of -106. 4, -126. 2, -125. 7, and -127. 8, respectively. Molecular dynamics simulations lasting 500 ns were performed to assess their stability and binding interactions. Further analyses, including MMGBSA, RMSD, RMSF, and hydrogen bond analysis, confirmed the stability and strong binding interactions of the peptide-protein complexes, suggesting that MSK-4 is a promising therapeutic agent for further development. We believe that the peptides generated through AI and MD simulations in the current study could be potential inhibitors in natural systems that can be utilized in designing therapeutic strategies against SARS-CoV-2.

Open Access PDF

Concepts Keywords
Antiviral Antiviral Agents
Coronavirus Antiviral Agents
Molecular COVID-19
Trained COVID-19 Drug Treatment
Deep Learning
deep learning
Drug Design
Humans
molecular docking
Molecular Docking Simulation
Molecular Dynamics Simulation
molecular dynamics simulation
Omicron variant
Peptides
Peptides
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
variational autoencoders (VAE)
Virus Internalization
Wasserstein autoencoders (WAE)

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease IDO algorithm
disease IDO protein
disease IDO host
drug DRUGBANK Coenzyme M
disease MESH severe acute respiratory syndrome
disease MESH infectious diseases
disease MESH chronic hepatitis
disease MESH influenza
drug DRUGBANK Isoxaflutole
disease IDO quality
disease IDO process
disease IDO replication
drug DRUGBANK Flunarizine
drug DRUGBANK Water
drug DRUGBANK Amber
disease IDO production
drug DRUGBANK Pidolic Acid
pathway KEGG Endocytosis
disease IDO site
drug DRUGBANK Diphenylpyraline
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Indoleacetic acid
disease MESH rare disease
disease MESH viral infections
disease MESH cancers
pathway REACTOME Antimicrobial peptides
drug DRUGBANK Guanosine
drug DRUGBANK Efavirenz
drug DRUGBANK Pyrazinamide
disease MESH galactosemia III
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Piperine
drug DRUGBANK Lysozyme
drug DRUGBANK Sodium lauryl sulfate
disease IDO cell
pathway KEGG Motor proteins
pathway REACTOME Inflammasomes

Original Article

(Visited 9 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *